Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Abbott Laboratories launched its newest continuous glucose monitor in the U.S. on Thursday. The biosensor named Lingo is the first-ever targeted for people without diabetes. Please watch the video ...

Cardiovascular disease is rising, and Abbott Laboratories is well-positioned in the CVD treatment space. Read why I'm neutral ...

The Department of Justice announced an investigation into Abbott Laboratories' Michigan plant which was at center of a nationwide formula shortage in 2022. Abbott is recalling several of its ready ...

Abbott Laboratories closed $5.24 short of its 52-week high ($121.64), which the company achieved on March 8th.

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

Abbott Laboratories' (NYSE:ABT) stock up by 8.7% over the past three months. Since the market usually pay for a... We recently compiled a list of the Jim Cramer’s Top 10 Stock Picks You Can’t ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...